Role of IL-23 in the pathogenesis of psoriasis: a novel potential therapeutic target?

Bibliography

• D'Elios MM, Del Prete G, Amedei A. Targeting IL-23 in human diseases. Expert Opin Ther Targets 2010;14:759-74
   PubMed Web of Science ®Google Scholar
• Benson JM, Sachs CW, Treacy G, et al. Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab. Nat Biotechnol 2011;29:615-24
   PubMed Web of Science ®Google Scholar
• Lupardus PJ, Garcia KC. The structure of interleukin-23 reveals the molecular basis of p40 subunit sharing with interleukin-12. J Mol Biol 2008;382:931-41
   PubMed Web of Science ®Google Scholar
• Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000;13:715-25
   PubMed Web of Science ®Google Scholar
• Tang C, Chen S, Qian H, et al. Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology 2012;135:112-24
   PubMed Web of Science ®Google Scholar
• Piskin G, Sylva-Steenland RM, Bos JD, et al. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 2006;176:1908-15
   PubMed Web of Science ®Google Scholar
• Ma XT, Zhang XJ, Zhang B, et al. Expression and regulation of interleukin-23 subunits in human peripheral blood mononuclear cells and hematopoietic cell lines in response to various inducers. Cell Biol Int 2004;28:689-97
   PubMedGoogle Scholar
• Hochrein H, Shortman K, Vremec D, et al. Differential production of IL-12, IFN-alpha, and IFN-gamma by mouse dendritic cell subsets. J Immunol 2001;166:5448-55
   PubMed Web of Science ®Google Scholar
• Verreck FA, de Boer T, Langenberg DM, et al. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc Natl Acad Sci USA 2004;101:4560-5
   PubMed Web of Science ®Google Scholar
• Schuetze N, Schoeneberger S, Mueller U, et al. IL-12 family members: differential kinetics of their TLR4-mediated induction by Salmonella enteritidis and the impact of IL-10 in bone marrow-derived macrophages. Int Immunol 2005;17:649-59
   PubMed Web of Science ®Google Scholar
• Jefford M, Schnurr M, Toy T, et al. Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuli. Blood 2003;102:1753-63
   PubMed Web of Science ®Google Scholar
• Smits HH, van Beelen AJ, Hessle C, et al. Commensal Gram-negative bacteria prime human dendritic cells for enhanced IL-23 and IL-27 expression and enhanced Th1 development. Eur J Immunol 2004;34:1371-80
   PubMed Web of Science ®Google Scholar
• Schnurr M, Toy T, Shin A, et al. Extracellular nucleotide signaling by P2 receptors inhibits IL-12 and enhances IL-23 expression in human dendritic cells: a novel role for the cAMP pathway. Blood 2005;105:1582-9
   PubMed Web of Science ®Google Scholar
• Liu W, Ouyang X, Yang J, et al. AP-1 activated by toll-like receptors regulates expression of IL-23 p19. J Biol Chem 2009;284:24006-16
   PubMed Web of Science ®Google Scholar
• Kray AE, Carter RS, Pennington KN, et al. Positive regulation of IkappaB kinase signaling by protein serine/threonine phosphatase 2A. J Biol Chem 2005;280:35974-82
   PubMed Web of Science ®Google Scholar
• Chang J, Voorhees TJ, Liu Y, et al. Interleukin-23 production in dendritic cells is negatively regulated by protein phosphatase 2A. Proc Natl Acad Sci USA 2010;107:8340-5
   PubMed Web of Science ®Google Scholar
• Li S, Wang L, Berman MA, et al. RNAi screen in mouse astrocytes identifies phosphatases that regulate NF-kappaB signaling. Mol Cell 2006;24:497-509
   PubMed Web of Science ®Google Scholar
• Parham C, Chirica M, Timans J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 2002;168:5699-708
   PubMed Web of Science ®Google Scholar
• Beadling C, Slifka MK. Regulation of innate and adaptive immune responses by the related cytokines IL-12, IL-23, and IL-27. Arch Immunol Ther Exp (Warsz) 2006;54:15-24
   PubMedGoogle Scholar
• Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol 2007;25:221-42
   PubMed Web of Science ®Google Scholar
• van de Vosse E, Lichtenauer-Kaligis EG, van Dissel JT, et al. Genetic variations in the interleukin-12/interleukin-23 receptor (beta1) chain, and implications for IL-12 and IL-23 receptor structure and function. Immunogenetics 2003;54:817-29
   PubMedGoogle Scholar
• Cho SS, Bacon CM, Sudarshan C, et al. Activation of STAT4 by IL-12 and IFN-alpha: evidence for the involvement of ligand-induced tyrosine and serine phosphorylation. J Immunol 1996;157:4781-9
   PubMed Web of Science ®Google Scholar
• Bacon CM, Petricoin EF III, Ortaldo JR, et al. Interleukin 12 induces tyrosine phosphorylation and activation of STAT4 in human lymphocytes. Proc Natl Acad Sci USA 1995;92:7307-11
   PubMed Web of Science ®Google Scholar
• Tato CM, Cua DJ. Reconciling id, ego, and superego within interleukin-23. Immunol Rev 2008;226:103-11
   PubMed Web of Science ®Google Scholar
• Cho ML, Kang JW, Moon YM, et al. STAT3 and NF-kappaB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice. J Immunol 2006;176:5652-61
   PubMed Web of Science ®Google Scholar
• Lankford CS, Frucht DM. A unique role for IL-23 in promoting cellular immunity. J Leukoc Biol 2003;73(1):49-56
   PubMed Web of Science ®Google Scholar
• Chen Z, Laurence A, Lanno Y, et al. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc Natl Acad Sci USA 2006;103:8137-42
   PubMed Web of Science ®Google Scholar
• Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005;201:233-40
   PubMed Web of Science ®Google Scholar
• Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441:235-8
   PubMed Web of Science ®Google Scholar
• Mangan PR, Harrington LE, O'Quinn DB, et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006;441:231-4
   PubMed Web of Science ®Google Scholar
• Veldhoen M, Hocking RJ, Atkins CJ, et al. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006;24:179-89
   PubMed Web of Science ®Google Scholar
• Zhou L, Ivanov II, Spolski R, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007;8:967-74
   PubMed Web of Science ®Google Scholar
• Veldhoen M, Hocking RJ, Flavell RA, et al. Signals mediated by transforming growth factor-beta initiate autoimmune encephalomyelitis, but chronic inflammation is needed to sustain disease. Nat Immunol 2006;7:1151-6
   PubMed Web of Science ®Google Scholar
• Nurieva R, Yang XO, Martinez G, et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007;448:480-3
   PubMed Web of Science ®Google Scholar
• Korn T, Bettelli E, Gao W, et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007;448:484-7
   PubMed Web of Science ®Google Scholar
• Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, et al. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007;8:942-9
   PubMed Web of Science ®Google Scholar
• Evans HG, Suddason T, Jackson I, et al. Optimal induction of T helper 17 cells in humans requires T cell receptor ligation in the context of Toll-like receptor-activated monocytes. Proc Natl Acad Sci USA 2007;104:17034-9
   PubMed Web of Science ®Google Scholar
• Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007;8:950-7
   PubMed Web of Science ®Google Scholar
• van Beelen AJ, Zelinkova Z, Taanman-Kueter EW, et al. Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells. Immunity 2007;27:660-9
   PubMed Web of Science ®Google Scholar
• Chen Z, Tato CM, Muul L, et al. Distinct regulation of interleukin-17 in human T helper lymphocytes. Arthritis Rheum 2007;56:2936-46
   PubMed Web of Science ®Google Scholar
• Volpe E, Servant N, Zollinger R, et al. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol 2008;9:650-7
   PubMed Web of Science ®Google Scholar
• McGeachy MJ, Bak-Jensen KS, Chen Y, et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 2007;8:1390-7
   PubMed Web of Science ®Google Scholar
• Ciric B, El-behi M, Cabrera R, et al. IL-23 drives pathogenic IL-17-producing CD8+ T cells. J Immunol 2009;182:5296-305
   PubMed Web of Science ®Google Scholar
• Ortega C, Fernandez AS, Carrillo JM, et al. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J Leukoc Biol 2009;86:435-43
   PubMed Web of Science ®Google Scholar
• Laggner U, Di Meglio P, Perera G, et al. Identification of a novel pro-inflammatory human skin-homing Vc9Vd2 T cell subset with a potential role in psoriasis. J Immunol 2011;187:2783-93
   PubMed Web of Science ®Google Scholar
• Lin AM, Rubin CJ, Khandpur R, et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol 2011;187:490-500
   PubMed Web of Science ®Google Scholar
• Cai Y, Shen X, Ding C, et al. Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation. Immunity 2011;35:596-610
   PubMed Web of Science ®Google Scholar
• Roark CL, Simonian PL, Fontenot AP, et al. gammadelta T cells: an important source of IL-17. Curr Opin Immunol 2008;20:353-7
   PubMed Web of Science ®Google Scholar
• Conti HR, Shen F, Nayyar N, et al. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med 2009;206:299-311
   PubMed Web of Science ®Google Scholar
• Nigam P, Kwa S, Velu V, et al. Loss of IL-17-producing CD8 T cells during late chronic stage of pathogenic simian immunodeficiency virus infection. J Immunol 2011;186:745-53
   PubMedGoogle Scholar
• Happel KI, Dubin PJ, Zheng M, et al. Divergent roles of IL-23 and IL-12 in host defense against Klebsiella pneumoniae. J Exp Med 2005;202:761-9
   PubMed Web of Science ®Google Scholar
• Aujla SJ, Chan YR, Zheng M, et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med 2008;14:275-81
   PubMed Web of Science ®Google Scholar
• Shiomi S, Toriie A, Imamura S, et al. IL-17 is involved in Helicobacter pylori-induced gastric inflammatory responses in a mouse model. Helicobacter 2008;13:518-24
   PubMed Web of Science ®Google Scholar
• Burchill MA, Nardelli DT, England DM, et al. Inhibition of interleukin-17 prevents the development of arthritis in vaccinated mice challenged with Borrelia burgdorferi. Infect Immun 2003;71:3437-42
   PubMed Web of Science ®Google Scholar
• Raffatellu M, Santos RL, Verhoeven DE, et al. Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut. Nat Med 2008;14:421-8
   PubMed Web of Science ®Google Scholar
• Umemura M, Yahagi A, Hamada S, et al. IL-17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis bacille Calmette-Guerin infection. J Immunol 2007;178:3786-96
   PubMed Web of Science ®Google Scholar
• Burchill MA, Nardelli DT, England DM, et al. Inhibition of interleukin-17 prevents the development of arthritis in vaccinated mice challenged with Borrelia burgdorferi. Infect Immun 2003;71:3437-42
   PubMed Web of Science ®Google Scholar
• Okamoto Yoshida Y, Umemura M, et al. Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. J Immunol 2010;184:4414-22
   PubMed Web of Science ®Google Scholar
• Fedele G, Stefanelli P, Spensieri F, et al. Bordetella pertussis-infected human monocyte-derived dendritic cells undergo maturation and induce Th1 polarization and interleukin-23 expression. Infect Immun 2005;73:1590-7
   PubMed Web of Science ®Google Scholar
• Martin DA, Towne JE, Kricorian G, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol 2013;133:17-26
   PubMed Web of Science ®Google Scholar
• Bergboer JG, Zeeuwen PL, Schalkwijk J. Genetics of psoriasis: evidence for epistatic interaction between skin barrier abnormalities and immune deviation. J Invest Dermatol 2012;132:2320-1
   PubMed Web of Science ®Google Scholar
• Ingram JT. The approach to psoriasis. Br Med J 1953;2:591-4
   PubMed Web of Science ®Google Scholar
• Baker BS, Swain AF, Griffiths CE, et al. Epidermal T lymphocytes and dendritic cells in chronic plaque psoriasis: the effects of PUVA treatment. Scand J Immunol 1985;22:471-7
   PubMedGoogle Scholar
• Baker BS, Griffiths CE, Lambert S, et al. The effects of cyclosporin A on T lymphocyte and dendritic cell sub-populations in psoriasis. Br J Dermatol 1987;116:503-10
   PubMed Web of Science ®Google Scholar
• Valdimarsson H, Baker BS, Jónsdóttir I, et al. Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens? Immunol Today 1995;16:145-9
   PubMedGoogle Scholar
• Demidem A, Taylor JR, Grammer SF, Streilein JW. T-lymphocyte-activating properties of epidermal antigen-presenting cells from normal and psoriatic skin: evidence that psoriatic epidermal antigen-presenting cells resemble cultured normal Langerhans cells. J Invest Dermatol 1991;97:454-60
   PubMedGoogle Scholar
• Menssen A, Trommler P, Vollmer S, et al. Evidence for an antigen-specific cellular immune response in skin lesions of patients with psoriasis vulgaris. J Immunol 1995;155:4078-83
   PubMed Web of Science ®Google Scholar
• Gottlieb SL, Gilleaudeau P, Johnson R, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995;1:442-7
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Powles AV, Leonard JN, et al. Clearance of psoriasis with low dose cyclosporin. Br Med J (Clin Res Ed) 1986;293:731-2
   PubMed Web of Science ®Google Scholar
• Prinz J, Braun-Falco O, Meurer M, et al. Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis. Lancet 1991;338:320-1
   PubMed Web of Science ®Google Scholar
• Gudjonsson JE, Johnston A, Dyson M, et al. Mouse models of psoriasis. J Invest Dermatol 2007;127:1292-308
   PubMed Web of Science ®Google Scholar
• Wrone-Smith T, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. J Clin Invest 1996;98:1878-87
   PubMed Web of Science ®Google Scholar
• Austin LM, Ozawa M, Kikuchi T, et al. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999;113:752-9
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Ghilardi N, Xie MH, et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003;278:1910-14
   PubMed Web of Science ®Google Scholar
• Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005;6:1123-32
   PubMed Web of Science ®Google Scholar
• Trifari S, Kaplan CD, Tran EH, et al. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from TH-17, TH1 and TH2 cells. Nat Immunol 2009;10:864-71
   PubMed Web of Science ®Google Scholar
• Caruso R, Botti E, Sarra M, et al. Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med 2009;15(9):1013-15
   PubMed Web of Science ®Google Scholar
• Singh TP, Schön MP, Wallbrecht K, et al. Involvement of IL-9 in Th17-associated inflammation and angiogenesis of psoriasis. PLoS One 2013;8:e51752
   PubMed Web of Science ®Google Scholar
• Res PC, Piskin G, de Boer OJ, et al. Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One 2010;5:e14108
   PubMed Web of Science ®Google Scholar
• Hijnen D, Knol EF, Gent YY, et al. CD8(+) T cells in the lesional skin of atopic dermatitis and psoriasis patients are an important source of IFN-γ, IL-13, IL-17, and IL-22. J Invest Dermatol 2013;133:973-9
   PubMed Web of Science ®Google Scholar
• Albanesi C, Scarponi C, Pallotta S, et al. Chemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitment. J Exp Med 2009;206:249-58
   PubMed Web of Science ®Google Scholar
• Ganguly D, Chamilos G, Lande R, et al. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med 2009;206:1983-94
   PubMed Web of Science ®Google Scholar
• Lande R, Ganguly D, Facchinetti V, et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med 2011;3:73ra19
   PubMed Web of Science ®Google Scholar
• Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005;202:135-43
   PubMed Web of Science ®Google Scholar
• Lowes MA, Chamian F, Abello MV, et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci USA 2005;102:19057-62
   PubMed Web of Science ®Google Scholar
• Zaba LC, Krueger JG, Lowes MA. Resident and “inflammatory” dendritic cells in human skin. J Invest Dermatol 2009;129:302-8
   PubMed Web of Science ®Google Scholar
• Nestle FO, Turka LA, Nickoloff BJ. Characterization of dermal dendritic cells in psoriasis: autostimulation of T lymphocytes and induction of Th1 type cytokines. J Clin Invest 1994;94:202-9
   PubMed Web of Science ®Google Scholar
• Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361(5):496-509
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Guttman-Yassky E, Suárez-Fariñas M, et al. Integrative responses to IL-17 and TNF-alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 2011;131(3):677-87
   PubMed Web of Science ®Google Scholar
• Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008;128:1207-11
   PubMed Web of Science ®Google Scholar
• Li J, Chen X, Liu Z, et al. Expression of Th17 cytokines in skin lesions of patients with psoriasis. J Huazhong Univ Sci Technolog Med Sci 2007;27:330-2
   PubMedGoogle Scholar
• Kagami S, Rizzo HL, Lee JJ, et al. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 2010;130:1373-83
   PubMed Web of Science ®Google Scholar
• Ortega C, Fernandez AS, Carrillo JM, et al. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J Leukoc Biol 2009;86:435-43
   PubMed Web of Science ®Google Scholar
• Takahashi H, Tsuji H, Hashimoto Y, et al. Serum cytokines and growth factor levels in Japanese patients with psoriasis. Clin Exp Dermatol 2010;35:645-9
   PubMed Web of Science ®Google Scholar
• Caproni M, Antiga E, Melani L, et al. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol 2009;29:210-14
   PubMed Web of Science ®Google Scholar
• Arican O, Aral M, Sasmaz S, et al. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005;2005:273-9
   PubMed Web of Science ®Google Scholar
• Chan JR, Blumenschein W, Murphy E, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006;203:2577-87
   PubMed Web of Science ®Google Scholar
• Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004;199:125-30
   PubMed Web of Science ®Google Scholar
• Nakajima K, Kanda T, Takaishi M, et al. Distinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse model. J Immunol 2011;186:4481-9
   PubMed Web of Science ®Google Scholar
• Hvid H, Teige I, Kvist PH, et al. TPA induction leads to a Th17-like response in transgenic K14/VEGF mice: a novel in vivo screening model of psoriasis. Int Immunol 20(8):1097-106
   PubMedGoogle Scholar
• van der Fits L, Mourits S, Voerman JS, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 2009;182:5836-45
   PubMed Web of Science ®Google Scholar
• Rizzo HL, Kagami S, Phillips KG, et al. IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. J Immunol 2011;186(3):1495-502
   PubMed Web of Science ®Google Scholar
• Watanabe H, Kawaguchi M, Fujishima S, et al. Functional characterization of IL-17F as a selective neutrophil attractant in psoriasis. J Invest Dermatol 2009;129:650-6
   PubMed Web of Science ®Google Scholar
• Fujishima S, Watanabe H, Kawaguchi M, et al. Involvement of IL-17F via the induction of IL-6 in psoriasis. Arch Dermatol Res 2010;302:499-505
   PubMed Web of Science ®Google Scholar
• Gaffen SL, Kramer JM, Yu JJ, Shen F. The IL-17 cytokine family. Vitam Horm 2006;74:255-82
   PubMed Web of Science ®Google Scholar
• Johnson-Huang LM, Suárez-Fariñas M, Sullivan-Whalen M, et al. Effective narrow-band UVB radiation therapy suppresses the IL-23/IL-17 axis in normalized psoriasis plaques. J Invest Dermatol 2010;130:2654-63
   PubMed Web of Science ®Google Scholar
• Haider AS, Lowes MA, Suárez-Fariñas M, et al. Identification of cellular pathways of “type 1,” Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis. J Immunol 2008;180:1913-20
   PubMed Web of Science ®Google Scholar
• Singh TP, Schön MP, Wallbrecht K, et al. 8-methoxypsoralen plus ultraviolet A therapy acts via inhibition of the IL-23/Th17 axis and induction of Foxp3+ regulatory T cells involving CTLA4 signaling in a psoriasis-like skin disorder. J Immunol 2010;184:7257-67
   PubMed Web of Science ®Google Scholar
• Zaba LC, Suárez-Fariñas M, Fuentes-Duculan J, et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol 2009;124:1022-10
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 2013;168:412-21
   PubMed Web of Science ®Google Scholar
• Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012;366:1190-9
   PubMed Web of Science ®Google Scholar
• Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012;366:1181-9
   PubMed Web of Science ®Google Scholar
• Alexander W. American Academy of Dermatology Cardiovascular Research Technologies 2013 American College of Cardiology. P T 2013;38:288-92
   PubMedGoogle Scholar
• Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665-74
   PubMed Web of Science ®Google Scholar
• Benson JM, Sachs CW, Treacy G, et al. Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab. Nat Biotechnol 2011;29:615-24
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010;362:118-28
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Leonardi C, Griffiths CE, et al. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. J Am Acad Dermatol 2012;66:731-41
   PubMed Web of Science ®Google Scholar
• Wada Y, Cardinale I, Khatcherian A, et al. Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis. PLoS One 2012;7:e35069
   PubMed Web of Science ®Google Scholar
• Available from: http://clinicaltrials.gov/ct2/results?term=CNTO+1959+AND+psoriasis
   Google Scholar
• Available from: http://clinicaltrials.gov/ct2/results?term=BI655066+AND+PSORIASIS&Search
   Google Scholar
• Yu RY, Gallagher G. A naturally occurring, soluble antagonist of human IL-23 inhibits the development and in vitro function of human Th17 cells. J Immunol 2010;185:7302-8
   PubMed Web of Science ®Google Scholar